The Vioxx scandal has reignited discussions on pharmaceutical ethics, revealing how profit motives led to over 50,000 deaths before its withdrawal. Internal documents indicate that manufacturers often favor financial settlements for wrongdoings over patient safety, mirroring practices seen in other industries, such as automotive and insurance. This situation raises urgent ethical questions about corporate accountability and the increasing disregard for consumer welfare as businesses prioritize profit margins.